Anti-LAG-3 Antibody, Non-Fucosylated (BioBet-1726ZP) (CAT#: BioBet-1726ZP) Datasheet

LAG3

Lymphocyte-activation gene 3

Lymphocyte-activation gene 3, also known as LAG-3, is a protein which in humans is encoded by the LAG3 gene. LAG3, which was discovered in 1990 and was designated CD223 (cluster of differentiation 223) after the Seventh Human Leucocyte Differentiation Antigen Workshop in 2000, is a cell surface molecule with diverse biologic effects on T cell function. It is an immune checkpoint receptor and as such is the target of various drug development programs by pharmaceutical companies seeking to develop new treatments for cancer and autoimmune disorders. In soluble form it is also being developed as a cancer drug in its own right.

LAG3, CD223, lymphocyte activating 3

Human: 3902; Mouse: 16768

Human: P18627; Mouse: Q61790

Extracellular region or secreted; Plasma Membrane

Diseases associated with LAG3 include Smoldering Myeloma and Kyphoscoliotic Heart Disease. Among its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.

The main ligand of LAG3 is MHC class II, which has a higher binding force with CD4. [14] This protein negatively regulates cell proliferation, activation [15] and homeostasis of T cells in a similar manner to CTLA-4 and PD-1 [16] [17], and is reported to play a role in Treg inhibitory function. 18]

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

AGEN1746

Humanized

Human

This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.